stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. OSUR
    stockgist
    HomeTop MoversCompaniesConcepts
    OSUR logo

    OraSure Technologies, Inc.

    OSUR
    NASDAQ
    Healthcare
    Medical - Instruments & Supplies
    Bethlehem, PA, US501 employeesorasure.com
    $3.08
    +0.04(1.15%)

    Mkt Cap $213M

    $2.11
    $3.48

    52-Week Range

    At a Glance

    AI-generated

    OraSure Technologies, Inc.

    Revenue breakdown: Other Product And Services Revenues (42.2%), Hiv (23.8%), Molecular Products (20%).

    8-K
    OraSure Technologies filed an 8-K on March 30, 2026 releasing a presentation rebutting claims from activist Altai Capital Management.

    $213M

    Market Cap

    $111M

    Revenue

    -$66M

    Net Income

    Employees501
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Other Product And Services Revenues42.2%($304M)
    Hiv23.8%($171M)
    Molecular Products20%($144M)
    COVID195.6%($41M)
    Risk Assessment Testing2.8%($20M)
    Other Revenues1.4%($10M)
    Other Non Product Revenues1.4%($10M)
    Hcv1.4%($10M)
    Molecular Services0.9%($6M)
    Government Contract0.4%($3M)

    Revenue by Geography

    US82%($579M)
    Africa12.2%($86M)
    Europe3.4%($24M)
    Other Foreign Countries2.5%($17M)
    Activity

    What Changed Recently

    Management Change
    Mar 4, 2026

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 28

    Financial Results
    Feb 24, 2026

    Results of Operations and Financial Condition. On February 25, 2026, OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidat

    Regulation FD
    Mar 29, 2026

    of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie

    Regulation FD
    Jan 4, 2026

    and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabiliti

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    GNFTGenfit S.A.$8.95+4.07%$446M-11.6
    NAUTNautilus Biotechnology, I...$3.31-1.49%$418M-7.7
    CATXPerspective Therapeutics,...$4.41-0.34%$325M—
    PREPrenetics Global Limited$19.73+0.79%$277M-5.9
    UTMDUtah Medical Products, In...$63.34+0.75%$203M19.1
    TARAProtara Therapeutics, Inc...$5.11+1.29%$197M-4.1
    PROFProfound Medical Corp.$6.39-2.14%$193M-3.6
    NYXHNyxoah S.A.$3.56+12.15%$133M-1.2
    Analyst View
    Company Profile
    CIK0001116463
    ISINUS68554V1089
    CUSIP68554V108
    Phone610 882 1820
    Address220 East First Street, Bethlehem, PA, 18015, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice